Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A peripheral blood extracellular vesicle microrna biomarker for early diagnosis of lung cancer and its application

A biomarker and early diagnosis technology, applied in the field of early detection of diseases, can solve the problems of little research, no discovery and verification of biomarkers for early diagnosis of lung cancer, etc.

Active Publication Date: 2020-08-14
上海思路迪医学检验所有限公司
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, blood extracellular vesicle miRNA as a biomarker has been less studied in the identification of benign and malignant pulmonary nodules, and no biomarkers have been found and validated to improve the specificity of early diagnosis of lung cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A peripheral blood extracellular vesicle microrna biomarker for early diagnosis of lung cancer and its application
  • A peripheral blood extracellular vesicle microrna biomarker for early diagnosis of lung cancer and its application
  • A peripheral blood extracellular vesicle microrna biomarker for early diagnosis of lung cancer and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0061] Example 1: Establishment and verification of a risk scoring model using 5 miRNAs as biomarkers

[0062] (1) Risk scoring model for benign and malignant pulmonary nodules

[0063]Using the miRNA expression data of the training cohort, with five biomarkers as variables, combined with pathological detection results, a risk scoring model for benign and malignant pulmonary nodules was constructed. The model consists of three parts: parameter, model formula and reference value. The process is as follows:

[0064] ① Model parameters. In the training cohort, with 5 biomarkers as variables, 100 times of repeated 10-fold cross-validation method was used to obtain model calibration parameters and model coefficients of biomarkers (Table 2).

[0065] Table 2. Parameters of the risk scoring model constructed with 5 miRNAs as biomarkers

[0066]

[0067] ② Risk scoring model. The risk scoring model formula is as follows:

[0068]

[0069] Among them, Risk-Score is the risk...

Embodiment 2

[0078] Example 2: Expansion of risk scoring model research - using 3 miRNAs as biomarkers

[0079] The risk score model expansion study found that when the biomarkers were combined with 5 miRNAs (hsa-let-7b-3p, hsa-miR-125b-5p, hsa-miR-150-5p, hsa-miR-101-3p, hsa- miR-3168) as the core, reducing or increasing the number of some miRNAs can also obtain higher prediction performance.

[0080] Using 3 miRNAs as markers, hsa-let-7b-3p, hsa-miR-101-3p and hsa-miR-3168 as biomarkers, the method was the same as above, and a risk scoring model was constructed (Table 4), with 0.77 as the reference Ratio, also can get higher AUC (0.914) and specificity (94.1%) ( Figure 5 ).

[0081] Table 4. Parameters of the risk scoring model constructed with 3 miRNAs as markers

[0082]

Embodiment 3

[0083] Example 3 Expansion of Risk Scoring Model Research - Using 8 miRNAs as Markers

[0084] On the basis of the 5 core biomarkers, hsa-let-7d-3p, hsa-miR-19b-3p and hsa-miR-503-5p were newly added as 8 variable biomarkers to construct a risk scoring model (Table 5) , using 0.79 as the reference value, can also obtain higher AUC (0.920) and specificity (94.1%) ( Figure 6 ).

[0085] Table 5. Parameters of the risk scoring model constructed with 8 miRNAs as markers

[0086]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

The invention discloses a peripheral blood extracellular vesicle miRNA biomarker for early diagnosis of lung cancer, characterized in that the peripheral blood extracellular vesicle miRNA biomarker includes hsa-let-7b-3p, hsa-let-7b-3p, hsa-let-7b-3p miR‑125b‑5p, hsa‑miR‑150‑5p, hsa‑miR‑101‑3p, hsa‑miR‑3168. The present invention is based on the peripheral blood of patients with pulmonary nodules detected by LDCT as a research sample, which has higher specificity and is more reliable. The research results are useful for accurately identifying false positive lung cancer patients from patients with pulmonary nodules detected by LDCT. important meaning.

Description

technical field [0001] The invention relates to the technical field of early detection of diseases, in particular to a peripheral blood extracellular vesicle microRNA biomarker for early diagnosis of lung cancer. Background technique [0002] Lung cancer is a malignant tumor with the highest morbidity and mortality worldwide. The early stage of lung cancer is hidden and usually asymptomatic, but most patients are already in the middle and late stages when they are first diagnosed, and have lost the opportunity for surgical resection. The five-year survival rate of advanced lung cancer patients is less than 5%, while the five-year survival rate of early lung cancer patients can reach more than 90%. Therefore, early diagnosis is an important opportunity for lung cancer patients to obtain a good prognosis. [0003] Lung cancer often presents in the early stages as lung nodules. The rapid development of imaging technology has improved the detection rate of pulmonary nodules. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/6886G16B5/00G16B40/00
CPCC12Q1/6886C12Q2600/158C12Q2600/178G16B5/00G16B40/00
Inventor 郑迪杨洋王慧珍张继扬张大东陈灏许晓雅李福根
Owner 上海思路迪医学检验所有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com